Fusion Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fusion Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Fusion Pharmaceuticals: 4 sponsored US clinical trials, 1 recruiting.
Fusion Pharmaceuticals sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Castration-Resistant Prostate Cancer, with 2 trials.
Upper-quartile sponsor footprint
Fusion Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06402331
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
NCT05219500
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
NCT05363605
A Phase 1 Study of [225Ac]-FPI-1434 Injection
NCT03746431
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Fusion Pharmaceuticals pipeline
1 recruiting of 4 indexed (25% open).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Metastatic Castration-Resistant Prostate Cancer (2 trials), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fusion Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Fusion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Fusion Pharmaceuticals page
4 registered trials is a research-attention snapshot, not an endorsement of Fusion Pharmaceuticals or any single study.
- 1 of Fusion Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Metastatic Castration-Resistant Prostate Cancer is the condition Fusion Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Castration-Resistant Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Fusion Pharmaceuticals pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.